Financial Statements

Arrowhead Pharmaceuticals, Inc. (ARWR)


+0.74 (+3.11%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands , Years are calendar years not fiscal years

Retained Earning Schedule

Year 2023 2022 2021 2020 2019
Retained Earnings (Previous Year) -821-645-504-419-
Net Income -205-176-141-8568
Stock Dividends -00--487
Dividend Paid -----
Retained Earnings -1,026-821-645-504-419

PPE Schedule

Year 2023 2022 2021 2020 2019
Gross PPE 169664723-
Annual Depreciation 344155433635
Capital Expenditure -177-53-24-12-12
Net PPE 336169664723

Intangible and Goodwill Schedule

Year 2023 2022 2021 2020 2019
Intangible and Goodwill (Previous Year) -----
New Purchases -90-279-241-223-246
Intangible and Goodwill -----

Arrowhead Pharmaceuticals, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Arrowhead Pharmaceuticals, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.